{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:01:08Z","timestamp":1792555268191,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04947-w","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T22:52:44Z","timestamp":1777848764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biopsy-proven tumefactive demyelinating lesions: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8223-6366","authenticated-orcid":false,"given":"Majed Abdullah","family":"Alaskar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munirah","family":"Alissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-5533","authenticated-orcid":false,"given":"Naif","family":"Alsaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-7924","authenticated-orcid":false,"given":"Salman","family":"Aljarallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"4947_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.msard.2017.04.003","volume":"14","author":"H Algahtani","year":"2017","unstructured":"Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: A comprehensive review. Multiple Scler Relat Disorders. 2017;14:72\u20139. https:\/\/doi.org\/10.1016\/j.msard.2017.04.003.","journal-title":"Multiple Scler Relat Disorders"},{"key":"4947_CR2","doi-asserted-by":"publisher","first-page":"868525","DOI":"10.3389\/fneur.2022.868525","volume":"13","author":"AG Vakrakou","year":"2022","unstructured":"Vakrakou AG, Brinia M-E, Svolaki I, Argyrakos T, Stefanis L, Kilidireas C. Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases. Front Neurol. 2022;13:868525. https:\/\/doi.org\/10.3389\/fneur.2022.868525.","journal-title":"Front Neurol"},{"key":"4947_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/WCO.0000000000000683","volume":"32","author":"TA Hardy","year":"2019","unstructured":"Hardy TA. Pseudotumoral demyelinating lesions: diagnostic approach and long-term outcome. Curr Opin Neurol. 2019;32:467\u201374. https:\/\/doi.org\/10.1097\/WCO.0000000000000683.","journal-title":"Curr Opin Neurol"},{"key":"4947_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1136\/jnnp-2012-304498","volume":"84","author":"TA Hardy","year":"2013","unstructured":"Hardy TA, Chataway J. Tumefactive demyelination: an approach to diagnosis and management. J Neurol Neurosurg Psychiatry. 2013;84:1047\u201353. https:\/\/doi.org\/10.1136\/jnnp-2012-304498.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4947_CR5","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.3892\/ol.2015.3481","volume":"10","author":"W Qi","year":"2015","unstructured":"Qi W, Jia G, Wang X, Zhang M, Ma Z. Cerebral tumefactive demyelinating lesions. Oncol Lett. 2015;10:1763\u20138. https:\/\/doi.org\/10.3892\/ol.2015.3481.","journal-title":"Oncol Lett"},{"key":"4947_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.17712\/nsj.2024.3.20230111","volume":"29","author":"YM Al Malik","year":"2024","unstructured":"Al Malik YM. Tumefactive demyelinating lesions: A literature review of recent findings. NSJ. 2024;29:153\u201360. https:\/\/doi.org\/10.17712\/nsj.2024.3.20230111.","journal-title":"NSJ"},{"key":"4947_CR7","first-page":"307","volume":"12","author":"M van der Velden","year":"1979","unstructured":"van der Velden M, Bots GT, Endtz LJ. Cranial CT in multiple sclerosis showing a mass effect. Surg Neurol. 1979;12:307\u201310.","journal-title":"Surg Neurol"},{"key":"4947_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.clineuro.2004.02.004","volume":"106","author":"CM Poser","year":"2004","unstructured":"Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg. 2004;106:147\u201358. https:\/\/doi.org\/10.1016\/j.clineuro.2004.02.004.","journal-title":"Clin Neurol Neurosurg"},{"key":"4947_CR9","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/14737175.2021.1971077","volume":"21","author":"P S\u00e1nchez","year":"2021","unstructured":"S\u00e1nchez P, Chan F, Hardy TA. Tumefactive demyelination: updated perspectives on diagnosis and management. Expert Rev Neurother. 2021;21:1005\u201317. https:\/\/doi.org\/10.1080\/14737175.2021.1971077.","journal-title":"Expert Rev Neurother"},{"key":"4947_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5144\/0256-4947.2003.291","volume":"23","author":"A Reis","year":"2003","unstructured":"Reis A, Cakir E, Cobanoglu U, Usul H, Kuzeyli K. Demyelinating Pseudotumor Cerebri: A Case Report. Ann Saudi Med. 2003;23:291\u20133. https:\/\/doi.org\/10.5144\/0256-4947.2003.291.","journal-title":"Ann Saudi Med"},{"key":"4947_CR11","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1177\/1352458516641776","volume":"22","author":"TA Hardy","year":"2016","unstructured":"Hardy TA, Tobin WO, Lucchinetti CF. Exploring the overlap between multiple sclerosis, tumefactive demyelination and Bal\u00f3\u2019s concentric sclerosis. Mult Scler. 2016;22:986\u201392. https:\/\/doi.org\/10.1177\/1352458516641776.","journal-title":"Mult Scler"},{"key":"4947_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10143-009-0185-5","volume":"32","author":"L Xia","year":"2009","unstructured":"Xia L, Lin S, Wang Z, Li S, Xu L, Wu J, et al. Tumefactive demyelinating lesions: nine cases and a review of the literature. Neurosurg Rev. 2009;32:171\u20139. https:\/\/doi.org\/10.1007\/s10143-009-0185-5.","journal-title":"Neurosurg Rev"},{"key":"4947_CR13","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/acn3.51844","volume":"10","author":"M Fereidan-Esfahani","year":"2023","unstructured":"Fereidan-Esfahani M, Decker PA, Weigand SD, Lopez Chiriboga AS, Flanagan EP, Tillema J, et al. Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients. Ann Clin Transl Neurol. 2023;10:1544\u201355. https:\/\/doi.org\/10.1002\/acn3.51844.","journal-title":"Ann Clin Transl Neurol"},{"key":"4947_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/adpa.2002.35737","volume":"6","author":"IE Erana-Rojas","year":"2002","unstructured":"Erana-Rojas IE, Barboza-Quintana A, Ayala AG, Fuller GN. Demyelinating pseudotumor. Annals Diagn Pathol. 2002;6:265\u201371. https:\/\/doi.org\/10.1053\/adpa.2002.35737.","journal-title":"Annals Diagn Pathol"},{"key":"4947_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.17712\/1658-3183.1421","volume":"11","author":"F Ziad","year":"2006","unstructured":"Ziad F, Katchy KC, Panda SM, Alexander S, Al-Sheikh T. Inflammatory demyelinating pseudotumor. Neurosciences (Riyadh). 2006;11:191\u20133.","journal-title":"Neurosciences (Riyadh)"},{"key":"4947_CR16","doi-asserted-by":"publisher","first-page":"7773","DOI":"10.1038\/s41598-023-34420-4","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang T, Zhang X, Yan X, Lei J, Liu R, et al. Clinical spectrum and prognosis of pathologically confirmed atypical tumefactive demyelinating lesions. Sci Rep. 2023;13:7773. https:\/\/doi.org\/10.1038\/s41598-023-34420-4.","journal-title":"Sci Rep"},{"key":"4947_CR17","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/brain\/awn098","volume":"131","author":"CF Lucchinetti","year":"2008","unstructured":"Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, Weigand S, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008;131:1759\u201375. https:\/\/doi.org\/10.1093\/brain\/awn098.","journal-title":"Brain"},{"key":"4947_CR18","doi-asserted-by":"publisher","first-page":"104992","DOI":"10.1016\/j.msard.2023.104992","volume":"79","author":"SH Chew","year":"2023","unstructured":"Chew SH, Achmad Sankala HB, Chew E, Md Arif MHB, Mohd Zain NR, Hashim H, et al. Tumefactive demyelinating lesions versus CNS neoplasms, a comparative study. Multiple Scler Relat Disorders. 2023;79:104992. https:\/\/doi.org\/10.1016\/j.msard.2023.104992.","journal-title":"Multiple Scler Relat Disorders"},{"key":"4947_CR19","doi-asserted-by":"publisher","unstructured":"Smith C, Finan M, Axelband J, Williams K. It is not a tumor: a rare case of tumefactive multiple sclerosis. Am J Emerg Med. 2014;32:946.e1-946.e3. https:\/\/doi.org\/10.1016\/j.ajem.2014.01.026.","DOI":"10.1016\/j.ajem.2014.01.026"},{"key":"4947_CR20","doi-asserted-by":"publisher","first-page":"1052678","DOI":"10.3389\/fimmu.2022.1052678","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, Miao X, Wang Y, Sun J, Gao H, Han J, et al. Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations. Front Immunol. 2022;13:1052678. https:\/\/doi.org\/10.3389\/fimmu.2022.1052678.","journal-title":"Front Immunol"},{"key":"4947_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"key":"4947_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4103\/aian.AIAN_185_21","volume":"25","author":"S Sivadasan","year":"2022","unstructured":"Sivadasan S, Poyuran R. Tumefactive Demyelination\u2014A Rare Presentation of Anti-MOG Syndrome. Ann Indian Acad Neurol. 2022;25:138\u201340. https:\/\/doi.org\/10.4103\/aian.AIAN_185_21.","journal-title":"Ann Indian Acad Neurol"},{"key":"4947_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s13760-021-01695-1","volume":"122","author":"Y-X Zhang","year":"2022","unstructured":"Zhang Y-X, Zheng Y, Cai M-T, Du Q, Ding M-P. MOG antibody-associated disease presenting with tumefactive lesions and closed-ring enhancement. Acta Neurol Belg. 2022;122:551\u20133. https:\/\/doi.org\/10.1007\/s13760-021-01695-1.","journal-title":"Acta Neurol Belg"},{"key":"4947_CR24","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s10072-023-06686-z","volume":"44","author":"M Salunkhe","year":"2023","unstructured":"Salunkhe M, Gupta P, Singh RK, Tayade K, Goel V, Agarwal A, et al. Clinical and radiological spectrum of anti-myelin oligodendrocyte glycoprotein (MOG) antibody encephalitis: single-center observational study. Neurol Sci. 2023;44:2475\u201389. https:\/\/doi.org\/10.1007\/s10072-023-06686-z.","journal-title":"Neurol Sci"},{"key":"4947_CR25","doi-asserted-by":"publisher","unstructured":"Cacciaguerra L, Morris P, Tobin WO, Chen JJ, Banks SA, Elsbernd P, et al. Tumefactive Demyelination in MOG Ab\u2013Associated Disease, Multiple Sclerosis, and AQP-4-IgG\u2013Positive Neuromyelitis Optica Spectrum Disorder. Neurology. 2023;100. https:\/\/doi.org\/10.1212\/WNL.0000000000206820.","DOI":"10.1212\/WNL.0000000000206820"},{"key":"4947_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5603\/PJNNS.a2022.0044","volume":"56","author":"TA Topkan","year":"2022","unstructured":"Topkan TA, Sokmen O, Kocer B, Karabudak R, Gocun PU. Tumefactive demyelinating lesion in patient with neuromyelitis optica spectrum disorder. Neurol Neurochir Pol. 2022;56:285\u20137. https:\/\/doi.org\/10.5603\/PJNNS.a2022.0044.","journal-title":"Neurol Neurochir Pol"},{"key":"4947_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/0028-3886.279688","volume":"68","author":"M Z Ghali","year":"2020","unstructured":"Z Ghali M. Tumefactive Acute Disseminated Encephalomyelitis. Neurol India. 2020;68:35. https:\/\/doi.org\/10.4103\/0028-3886.279688.","journal-title":"Neurol India"},{"key":"4947_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.msard.2019.07.013","volume":"35","author":"M Silsby","year":"2019","unstructured":"Silsby M, S\u00e1nchez P, Spies JM, Frith J, Barton J, Beadnall HN, et al. Investigation of tumefactive demyelination is associated with higher economic burden and more adverse events compared with conventional multiple sclerosis. Multiple Scler Relat Disorders. 2019;35:104\u20137. https:\/\/doi.org\/10.1016\/j.msard.2019.07.013.","journal-title":"Multiple Scler Relat Disorders"},{"key":"4947_CR29","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"4947_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"4947_CR31","doi-asserted-by":"publisher","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Database Syst Reviews Implement Rep. 2019;Publish Ahead of Print. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099","DOI":"10.11124\/JBISRIR-D-19-00099"},{"key":"4947_CR32","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Comprehensive Meta-Analysis, Version 3. 2013."},{"key":"4947_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ EBM. 2018;23:60\u20133. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853.","journal-title":"BMJ EBM"},{"key":"4947_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ccr3.58","volume":"2","author":"D Jackson","year":"2014","unstructured":"Jackson D, Daly J, Saltman DC. Aggregating case reports: a way for the future of evidence-based health care? Clin Case Rep. 2014;2:23\u20134. https:\/\/doi.org\/10.1002\/ccr3.58.","journal-title":"Clin Case Rep"},{"key":"4947_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13023-019-1202-6","volume":"14","author":"M Sampayo-Cordero","year":"2019","unstructured":"Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Malfettone A, P\u00e9rez-Garc\u00eda J, Llombart-Cussac A, et al. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases. Orphanet J Rare Dis. 2019;14:230. https:\/\/doi.org\/10.1186\/s13023-019-1202-6.","journal-title":"Orphanet J Rare Dis"},{"key":"4947_CR36","doi-asserted-by":"publisher","first-page":"205521731985575","DOI":"10.1177\/2055217319855755","volume":"5","author":"SA Brod","year":"2019","unstructured":"Brod SA, Lindsey JW, Nelson F. Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments. Multiple Scler J - Experimental Translational Clin. 2019;5:2055217319855755. https:\/\/doi.org\/10.1177\/2055217319855755.","journal-title":"Multiple Scler J - Experimental Translational Clin"},{"key":"4947_CR37","doi-asserted-by":"publisher","first-page":"1092373","DOI":"10.3389\/fneur.2023.1092373","volume":"14","author":"T Boyle","year":"2023","unstructured":"Boyle T, Fernando SL, Drummond J, Fontes A, Parratt J. Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological features\u2014A case series. Front Neurol. 2023;14:1092373. https:\/\/doi.org\/10.3389\/fneur.2023.1092373.","journal-title":"Front Neurol"},{"key":"4947_CR38","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/s41598-024-52048-w","volume":"14","author":"T Ongphichetmetha","year":"2024","unstructured":"Ongphichetmetha T, Aungsumart S, Siritho S, Apiwattanakul M, Tanboon J, Rattanathamsakul N, et al. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand. Sci Rep. 2024;14:1426. https:\/\/doi.org\/10.1038\/s41598-024-52048-w.","journal-title":"Sci Rep"},{"key":"4947_CR39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.msard.2018.09.002","volume":"26","author":"TA Nazareth","year":"2018","unstructured":"Nazareth TA, Rava AR, Polyakov JL, Banfe EN, Waltrip Ii RW, Zerkowski KB, et al. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey. Multiple Scler Relat Disorders. 2018;26:219\u201334. https:\/\/doi.org\/10.1016\/j.msard.2018.09.002.","journal-title":"Multiple Scler Relat Disorders"},{"key":"4947_CR40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jns.2017.08.015","volume":"381","author":"MA Tremblay","year":"2017","unstructured":"Tremblay MA, Villanueva-Meyer JE, Cha S, Tihan T, Gelfand JM. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions. J Neurol Sci. 2017;381:83\u20137. https:\/\/doi.org\/10.1016\/j.jns.2017.08.015.","journal-title":"J Neurol Sci"},{"key":"4947_CR41","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2214\/AJR.20.23226","volume":"217","author":"M Nakayama","year":"2021","unstructured":"Nakayama M, Naganawa S, Ouyang M, Jones KA, Kim J, Capizzano AA, et al. A Review of Clinical and Imaging Findings in Tumefactive Demyelination. Am J Roentgenol. 2021;217:186\u201397. https:\/\/doi.org\/10.2214\/AJR.20.23226.","journal-title":"Am J Roentgenol"},{"key":"4947_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.clineuro.2017.09.013","volume":"162","author":"RS Jain","year":"2017","unstructured":"Jain RS, Khan I, Kandelwal K, Desai T. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features. Clin Neurol Neurosurg. 2017;162:91\u20134. https:\/\/doi.org\/10.1016\/j.clineuro.2017.09.013.","journal-title":"Clin Neurol Neurosurg"},{"key":"4947_CR43","doi-asserted-by":"publisher","unstructured":"Valado A. Multiple Sclerosis: Oligoclonal IgG Bands, Prevalence, Prognosis and Effect of Latitude. BJSTR. 2020;28. https:\/\/doi.org\/10.26717\/bjstr.2020.28.004611.","DOI":"10.26717\/bjstr.2020.28.004611"},{"key":"4947_CR44","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1177\/1352458511431729","volume":"18","author":"J Lechner-Scott","year":"2012","unstructured":"Lechner-Scott J, Spencer B, De Malmanche T, Attia J, Fitzgerald M, Trojano M, et al. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Mult Scler. 2012;18:974\u201382. https:\/\/doi.org\/10.1177\/1352458511431729.","journal-title":"Mult Scler"},{"key":"4947_CR45","doi-asserted-by":"publisher","first-page":"14987","DOI":"10.1038\/s41598-021-94423-x","volume":"11","author":"VD Karrenbauer","year":"2021","unstructured":"Karrenbauer VD, Bedri SK, Hillert J, Manouchehrinia A. Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study. Sci Rep. 2021;11:14987. https:\/\/doi.org\/10.1038\/s41598-021-94423-x.","journal-title":"Sci Rep"},{"key":"4947_CR46","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/jnnp-2012-304695","volume":"84","author":"R Dobson","year":"2013","unstructured":"Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013;84:909\u201314. https:\/\/doi.org\/10.1136\/jnnp-2012-304695.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4947_CR47","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/biomedicines13020440","volume":"13","author":"R Candeloro","year":"2025","unstructured":"Candeloro R, Ferri C, Laudisi M, Baldi E, Pugliatti M, Castellazzi M. The Diagnostic Utility of Oligoclonal Bands in Multiple Sclerosis: A Time-Course Analysis. Biomedicines. 2025;13:440. https:\/\/doi.org\/10.3390\/biomedicines13020440.","journal-title":"Biomedicines"},{"key":"4947_CR48","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1212\/CPJ.0000000000000319","volume":"7","author":"X Lin","year":"2017","unstructured":"Lin X, Yu W-Y, Liauw L, Chander RJ, Soon WE, Lee HY, et al. Clinicoradiologic features distinguish tumefactive multiple sclerosis from CNS neoplasms. Neur Clin Pract. 2017;7:53\u201364. https:\/\/doi.org\/10.1212\/CPJ.0000000000000319.","journal-title":"Neur Clin Pract"},{"key":"4947_CR49","doi-asserted-by":"publisher","first-page":"146","DOI":"10.25259\/SNI_239_2022","volume":"13","author":"H French","year":"2022","unstructured":"French H, Fontes-Villalba A, Maharaj M, Naidoo CSY, Bhatia K, Paterson A, et al. Tumefactive multiple sclerosis versus high grade glioma: A diagnostic dilemma. Surg Neurol Int. 2022;13:146. https:\/\/doi.org\/10.25259\/SNI_239_2022.","journal-title":"Surg Neurol Int"},{"key":"4947_CR50","doi-asserted-by":"publisher","unstructured":"Monschein T, Ponleitner M, Bsteh G, Krajnc N, Zulehner G, Rommer P, et al. The presence of oligoclonal bands predicts conversion to multiple sclerosis in isolated myelitis. Sci Rep. 2024;14. https:\/\/doi.org\/10.1038\/s41598-024-71315-4.","DOI":"10.1038\/s41598-024-71315-4"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04947-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04947-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04947-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T22:23:03Z","timestamp":1782080583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04947-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4947"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04947-w","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"403"}}